Teva and Xenon rack up another setback as PhIIb study fails on every endpoint
The bad news is stacking up at Xenon Pharmaceuticals. Its most advanced drug just flopped in a Phase IIb at Teva, just three months after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
